- Home
- RIGL vs TCPC Comparison
RIGL vs TCPC Comparison
Compare RIGL & TCPC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | TCPC |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 537.6M | 449.7M |
| IPO Year | 2000 | 2012 |
Fundamental Metrics
Financial Performance| Metric | RIGL | TCPC |
|---|---|---|
| Price | $37.67 | $5.79 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 5 | 2 |
| Target Price | ★ $43.20 | $6.50 |
| AVG Volume (30 Days) | 585.3K | ★ 936.0K |
| Earning Date | 03-03-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 19.34% |
| EPS Growth | ★ 2698.26 | N/A |
| EPS | ★ 6.20 | N/A |
| Revenue | ★ $282,076,000.00 | $219,119,058.00 |
| Revenue This Year | $65.53 | N/A |
| Revenue Next Year | $0.22 | N/A |
| P/E Ratio | $6.05 | ★ N/A |
| Revenue Growth | ★ 79.13 | N/A |
| 52 Week Low | $15.50 | $5.29 |
| 52 Week High | $52.24 | $9.48 |
Technical Indicators
Market Signals| Indicator | RIGL | TCPC |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 56.62 |
| Support Level | $37.00 | $5.54 |
| Resistance Level | $39.49 | $5.90 |
| Average True Range (ATR) | 2.62 | 0.14 |
| MACD | -0.73 | 0.05 |
| Stochastic Oscillator | 4.46 | 80.70 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About TCPC BlackRock TCP Capital Corp.
BlackRock TCP Capital Corp is an externally-managed specialty finance company focused on middle-market lending. Its investment objective is to achieve high total returns through current income and capital appreciation, with an emphasis on principal protection. It seeks to achieve investment objective through investments in debt securities of middle-market companies. The group generates returns through a combination of the receipt of contractual interest payments on debt investments and origination and similar fees, and, to a lesser extent, equity appreciation through options, warrants, conversion rights or direct equity investments.